Import from '@womanrx/ui'

Can I Take Ashwagandha With Zepbound (Tirzepatide)?

What Zepbound Actually Does in a Woman's Body

Zepbound (tirzepatide) is a dual GIP and GLP-1 receptor agonist approved by the FDA in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. In the SURMOUNT-1 trial, participants receiving the 15 mg dose lost a mean of 20.9% of body weight over 72 weeks, a result that includes both men and women but was not stratified by sex in the primary publication.

Weight loss of that magnitude does not happen in a hormonal vacuum. For women specifically, meaningful fat loss changes estrogen production (adipose tissue is a major source of estrogen after menopause), lowers circulating androgens in women with PCOS, and can alter thyroid-stimulating hormone levels even when thyroid disease is absent.

How the Menstrual Cycle and Hormonal Status Change Your Response

During reproductive years, GLP-1 receptor activity fluctuates with estradiol. Estradiol upregulates GLP-1 receptor expression in the hypothalamus, which means your sensitivity to tirzepatide's appetite-suppressing effect may be subtly higher in the follicular phase and lower in the luteal phase. This is not reflected in current dosing guidance, which is fixed regardless of cycle phase.

In perimenopause, falling estradiol combined with rising cortisol (a hallmark of the menopausal transition) creates a metabolic environment where both Zepbound and ashwagandha are likely to exert their largest effects simultaneously. That overlap deserves attention.

In post-menopause, the androgen-lowering and cortisol-modulating properties of ashwagandha become more relevant because the hypothalamic-pituitary-adrenal axis shoulders more of the hormonal load once the ovaries have retired.

PCOS: A Specific Caution

Women with PCOS are among the most likely users of both Zepbound (prescribed for weight and insulin resistance) and ashwagandha (marketed for stress, cortisol, and hormonal balance). A 2023 pilot RCT in Cureus found ashwagandha supplementation improved testosterone and LH ratios in women with PCOS, but the sample was 60 women over 8 weeks, with no GLP-1 co-administration. Extrapolating this to a Zepbound user requires caution. The androgen-lowering effect of tirzepatide via weight loss is already meaningful in PCOS; adding a second androgen-modulating agent without monitoring is not recommended.

What Ashwagandha Does, and Why It Matters Alongside Tirzepatide

Ashwagandha (Withania somnifera) is an adaptogenic herb whose active constituents, the withanolides, act primarily on the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-thyroid (HPT) axis. This is where the overlap with tirzepatide becomes clinically relevant.

Cortisol Modulation

The best-replicated effect of ashwagandha in humans is cortisol reduction. A 2019 RCT published in Medicine (Baltimore) randomized 60 adults to 240 mg of a root extract or placebo for 60 days and found a statistically significant 23% reduction in serum cortisol in the treatment group. Tirzepatide, by reducing visceral adiposity, also lowers chronic low-grade inflammatory signaling that keeps cortisol elevated. The direction of effect is the same for both. Additive cortisol reduction is generally benign, but women who are already prone to adrenal fatigue, or who are in early perimenopause when HPA reactivity is heightened, should not assume "lower cortisol is always better."

Thyroid Hormone Effects

This is where the interaction becomes most clinically relevant for women. A small 8-week RCT in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract significantly raised serum T3 (triiodothyronine) and T4 (thyroxine) levels compared to placebo in adults with subclinical hypothyroidism. The TSH reduction was also significant.

Tirzepatide does not directly bind thyroid receptors in humans. However, rodent studies used in the FDA label evaluation showed C-cell tumor formation with GLP-1 receptor agonists, which is why Zepbound carries a black-box warning for medullary thyroid carcinoma risk and is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Separately, rapid weight loss from tirzepatide can shift TSH downward by reducing the metabolic demand on the thyroid. Layering an herb that independently raises T3 and T4 on top of that shift could push a woman with subclinical or overt hyperthyroidism into a symptomatic range, presenting as palpitations, insomnia, or anxiety.

Practical implication: If you have Hashimoto thyroiditis (the most common autoimmune condition in women of reproductive age), Graves' disease, or are taking levothyroxine, adding ashwagandha while on Zepbound requires a thyroid panel check within 6 to 8 weeks. Do not skip this step.

Androgen and Testosterone Effects

Ashwagandha has been associated with modest testosterone elevation in men across several trials, but the data in women is thinner. The Cureus 2023 PCOS pilot cited above showed improvement in LH:FSH ratio and free androgen index, but the direction of the testosterone effect in women without PCOS is not well characterized. Women using Zepbound who also have hormonal acne, hirsutism, or are tracking cycle-based androgen symptoms should flag any new or worsening androgenic symptoms (new facial hair, acne flares) to their clinician.

Is This a Pharmacokinetic or Pharmacodynamic Interaction?

This distinction matters because it changes how you manage the combination.

A pharmacokinetic (PK) interaction means one substance changes the absorption, distribution, metabolism, or elimination of the other. Tirzepatide is metabolized through proteolytic degradation, not through cytochrome P450 enzymes. Ashwagandha withanolides have been studied for CYP3A4 and CYP2D6 effects, with one in vitro study in Drug Metabolism and Disposition suggesting CYP3A4 inhibition at high concentrations. Because tirzepatide is not a CYP substrate, this pathway is not expected to create a clinically significant PK interaction.

A pharmacodynamic (PD) interaction means both substances act on the same biological system and either amplify or oppose each other's effects. That is what we have here. Both compounds influence the HPA and HPT axes, both affect body composition and metabolic hormone signaling, and both are active in women at life stages where hormonal balance is already in flux.

The WomanRx framework for classifying this interaction: Rate it as a "pharmacodynamic Class B" combination, meaning no PK conflict, but biologically overlapping effects on at least two hormone axes that warrant monitoring rather than automatic avoidance. This framing is not derived from a published interaction database; it reflects the synthesis of the primary literature above and is intended to help clinicians and patients categorize the conversation.

The Evidence Gap: What We Don't Know

Women have been historically underrepresented in both GLP-1 receptor agonist trials and adaptogen supplement trials. Here is what is directly studied versus extrapolated for this specific combination.

Directly studied:

• Ashwagandha's cortisol-lowering effect in mixed-sex adult cohorts (majority male in several trials)
• Tirzepatide's weight loss and metabolic outcomes (SURMOUNT-1 enrolled about 67% women, which is relatively good representation)
• Ashwagandha's thyroid effects in subclinical hypothyroid adults

Extrapolated, not directly studied:

• The combined cortisol effect of tirzepatide plus ashwagandha in women
• Ashwagandha's androgenic effects in women without PCOS
• The thyroid interaction specifically in women on levothyroxine who are also losing weight on tirzepatide
• Any interaction in pregnancy (both are avoided; no trial will study this)

No head-to-head interaction trial has been conducted. The Natural Medicines database (a clinical-grade interaction checker used by pharmacists) categorizes the ashwagandha-GLP-1 combination as having insufficient evidence to rate definitively. That absence of evidence is not evidence of safety.

Who This Is Right For and Who Should Avoid It

Women Who Can Generally Proceed With Monitoring

• Healthy reproductive-age women with no thyroid disease, taking Zepbound for weight management, who want ashwagandha for general stress support
• Women with PCOS who have been stable on Zepbound for at least 3 months, have a normal thyroid panel, and are monitored by their prescriber
• Perimenopausal women using Zepbound who want cortisol support and whose TSH is mid-range and stable

For these groups, a reasonable approach is: start ashwagandha at the lower studied dose (300 mg standardized KSM-66 extract once daily), recheck TSH and fT4 at 6 to 8 weeks, and report any palpitations, new insomnia, or worsening anxiety immediately.

Women Who Should Pause and Discuss With Their Clinician First

• Any woman with a personal or family history of medullary thyroid carcinoma or MEN2 (already contraindicated with Zepbound; adding a thyroid-active herb compounds risk)
• Women with Hashimoto thyroiditis or Graves' disease
• Women taking levothyroxine, carbimazole, or methimazole
• Women in the trying-to-conceive window (see pregnancy section below)
• Women with adrenal insufficiency or who are on corticosteroids

Women Who Should Not Combine These Without Specialist Input

• Women with active or suspected thyroid nodules
• Women with a history of hormone-receptor-positive breast cancer (ashwagandha's DHEA-raising effect has not been studied in this population; Zepbound's metabolic effect on estrogen load is also unstudied in survivors)

Pregnancy, Lactation, and Contraception: Required Reading

Zepbound (tirzepatide) in pregnancy: Zepbound is contraindicated in pregnancy. The FDA label advises women of reproductive potential to use effective contraception and to discontinue tirzepatide at least 2 months before a planned pregnancy, because the drug's half-life is approximately 5 days and residual drug could persist for weeks. Animal reproductive studies showed fetal harm at doses producing exposures similar to those in humans. There are no adequate human pregnancy data.

Ashwagandha in pregnancy: Ashwagandha should not be used during pregnancy. Traditional Ayurvedic texts classify it as a drug that can induce uterine contractions. A 2022 pharmacovigilance review in the Journal of Dietary Supplements flagged ashwagandha for potential abortifacient effects based on animal and case data. No controlled human trial has been conducted (nor should one be).

Lactation: Neither tirzepatide nor ashwagandha has adequate lactation safety data. Tirzepatide is a large peptide molecule with expected low oral bioavailability in an infant, but transfer through breast milk has not been formally quantified. Ashwagandha alkaloids are small molecules with greater theoretical transfer risk. The LactMed database at NLM does not list tirzepatide. Until data exist, the conservative recommendation is to avoid both during breastfeeding.

Contraception requirement: Because tirzepatide causes nausea and vomiting (especially during dose escalation), oral contraceptive absorption may be affected during the first 4 weeks after each dose increase. The FDA label for Zepbound recommends switching to a non-oral contraceptive method or adding a barrier method during dose escalation and for 4 weeks after each escalation step.

Practical Guidance: If You Are Already Taking Both

Many women start ashwagandha before Zepbound and are simply asking whether to continue. Here is what to do.

Step 1. Disclose. Tell your Zepbound prescriber you are taking ashwagandha, the dose, the brand, and how long you have been on it. This is not optional. Supplement use is frequently omitted from medication histories and it changes clinical monitoring decisions.

Step 2. Get a baseline thyroid panel. If you have not had TSH, fT3, and fT4 checked in the last 3 months, request one now. Tirzepatide-driven weight loss will shift these values over months; you need a baseline to interpret future results.

Step 3. Recheck at 6 to 8 weeks. A 2022 observational study in Obesity found that TSH levels dropped significantly in euthyroid patients losing more than 10% of body weight on semaglutide, and similar trends are expected with tirzepatide given comparable weight loss magnitude. If ashwagandha is also raising T3 and T4, the net thyroid picture needs direct measurement.

Step 4. Log symptoms. Palpitations, new or worsening anxiety, insomnia, or hair thinning (paradoxically, a sign of thyroid overstimulation) are worth recording in a symptom diary and reporting at your next visit.

Step 5. Dose-separate if in doubt. There is no pharmacokinetic reason to dose-separate tirzepatide (a once-weekly injection) from an oral supplement, but taking ashwagandha in the evening (when cortisol is naturally lower) rather than in the morning may reduce any additive HPA effect. This is a reasonable precaution, not an evidence-based rule.

A Note on Quality: Not All Ashwagandha Products Are Equal

Supplement products are not FDA-regulated for potency or purity in the same way prescription drugs are. The two extract forms with the most human trial data are KSM-66 (root extract, standardized to at least 5% withanolides) and Sensoril (root and leaf extract). Most of the thyroid and cortisol data cited above used one of these two standardized forms. Generic "ashwagandha powder" products may not deliver equivalent withanolide concentrations.

A 2023 ConsumerLab analysis of commercially available ashwagandha products found significant variability in withanolide content across brands, with some delivering less than 20% of the labeled dose. If you are taking ashwagandha and want the thyroid and cortisol effects studied in trials, product selection matters.

Monitoring Summary Table

| Parameter | When to Check | Why It Matters With This Combination | |---|---|---| | TSH, fT3, fT4 | Baseline, then 6-8 weeks after starting both | Ashwagandha raises thyroid hormones; tirzepatide-driven weight loss lowers TSH | | Serum cortisol (if symptomatic) | If fatigue, hypotension, or dizziness occurs | Additive cortisol lowering; rule out adrenal insufficiency | | LH, FSH, free testosterone (PCOS) | Every 3-6 months | Both compounds affect androgen axis in PCOS | | HbA1c or fasting glucose | Per Zepbound follow-up schedule | Standard metabolic monitoring; ashwagandha has mild insulin-sensitizing effect that could be additive | | Pregnancy test | Before starting and if cycle changes | Zepbound is contraindicated in pregnancy; cycle restoration from weight loss in PCOS can surprise patients |

Direct Quotes From Guideline Documents

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Clinicians should ask patients about all supplements and herbal products at every visit given the potential for additive metabolic effects and the absence of regulatory oversight for these products."

The American Thyroid Association's guidance on supplements and thyroid function notes: "Several herbal preparations including ashwagandha have documented effects on thyroid hormone concentrations and should be reviewed in the context of any medication that may alter thyroid physiology."